Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Dallas, Texas

Cancer biologic therapy trials in Dallas, TX

46 cancer biologic therapy studies are recruiting participants at sites in Dallas as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Dallas at a glance

  • 46 studies are recruiting at a site in Dallas.
  • By phase: Phase 1 (4), Phase 1/2 (8), Phase 2 (11), Phase 2/3 (1), Phase 3 (21), Observational (1).
  • By sponsor: industry (34), government (9), university, hospital or other (3).
  • By research area: Breast Cancer (12), Lung Cancer (12), Lymphoma (12), Melanoma (6), Prostate Cancer (4).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Dallas

Basic details from each study's public record (the 30 most recently updated of 46). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT05564377 · updated
  2. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Parkland Health & Hospital System ( Site 0096) · Texas Oncology - DFW ( Site 8000) · University of Texas Southwestern Medical Center ( Site 0032)
    Registry record
    NCT06393374 · updated
  3. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8007)
    Registry record
    NCT06841354 · updated
  4. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Texas Oncology - DFW ( Site 8009) · UT Southwestern ( Site 0092)
    Registry record
    NCT06966700 · updated
  5. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8000)
    Registry record
    NCT06797635 · updated
  6. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8003)
    Registry record
    NCT07060807 · updated
  7. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Parkland Health and Hospital System ( Site 0069) · Texas Oncology-Dallas Presbyterian Hospital ( Site 8000) · UT Southwestern Medical Center ( Site 0050)
    Registry record
    NCT06312176 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Lung cancer studies recruiting in Dallas

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  2. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Texas Oncology - DFW ( Site 8103) · UT Southwestern Medical Center ( Site 0190)
    Registry record
    NCT06623422 · updated
  3. Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8003)
    Registry record
    NCT06780098 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT04267848 · updated
  5. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT06096844 · updated
  6. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT04181060 · updated
  7. A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    • Phase 3
    • All ages
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study sites
    Baylor Scott and White Research Institute (Adults only) · University of Texas Southwestern Medical Center - Children's Medical Center (Pediatrics only)
    Registry record
    NCT03394365 · updated
  8. A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Moonlight Bio, Inc
    Study site
    UT Southwestern Medical Center
    Registry record
    NCT07488923 · updated
  9. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Texas Oncology - DFW
    Registry record
    NCT07222566 · updated
  10. Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genprex, Inc.
    Study site
    Texas Oncology - DFW
    Registry record
    NCT05703971 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Prostate cancer studies recruiting in Dallas

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT03866382 · updated
  2. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    UT Southwestern Medical Center
    Registry record
    NCT07164443 · updated
  3. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study sites
    Mary Crowley Cancer Research · University of Texas Southwestern Medical Center
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Melanoma studies recruiting in Dallas

  1. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0054)
    Registry record
    NCT02332668 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study sites
    Baylor University · University of Texas Southwestern Medical Center
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Dallas, TX on ClinicalTrials.gov.

Lymphoma studies recruiting in Dallas

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Medical City Dallas Hospital · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT06317662 · updated
  2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8000)
    Registry record
    NCT06717347 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UT Southwestern Medical Center ( Site 0190)
    Registry record
    NCT06890884 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Medical City Dallas Hospital · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Medical City Dallas Hospital · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT05675410 · updated
  6. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    Texas Oncology - Dallas Fort Worth
    Registry record
    NCT06500273 · updated
  7. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Medical City Dallas Hospital · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT06124157 · updated
  8. T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Estrella Immunopharma, Inc.
    Study site
    Baylor Scott & White Research Institute, Texas Oncology
    Registry record
    NCT06343311 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Dallas, TX on ClinicalTrials.gov.

Ask about studies near Dallas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call